Kiniksa Pharmaceuticals International, plc (KNSA) News
Follow Kiniksa Pharmaceuticals International, plc (KNSA) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 23 public stories across 6 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
Kiniksa Reports Third-Quarter Revenue of $285.97 Million
Kiniksa Pharmaceuticals reported third-quarter 2026 revenue of $285.97 million, up 58.1% year over year. Net income was $47.35 million and diluted EPS was $0.56; growth was driven primarily by more patients receiving ARC
EQUITY | Oct 27, 2026, 08:42 PM UTC
M
Kiniksa Pharmaceuticals Reports Quarterly Results Through September 30
LSEG-generated earnings summary for Kiniksa Pharmaceuticals covers the quarter ended September 30.
EQUITY | Oct 27, 2026, 01:31 PM UTC
M
Kiniksa Pharmaceuticals Reports Higher Q3 Net Income and Revenue
Kiniksa Pharmaceuticals said third-quarter net income and revenue rose.
EQUITY | Oct 27, 2026, 12:31 PM UTC
M
Kiniksa Pharmaceuticals Reports Third-Quarter Revenue of $286M
EQUITY | Oct 27, 2026, 11:41 AM UTC
M
Kiniksa Pharmaceuticals International Reports Q3 EPS of $0.56
Kiniksa reported Q3 EPS of $0.56, versus a FactSet estimate of $0.35.
EARNINGS | Oct 27, 2026, 11:37 AM UTC
M
Kiniksa Q3 2026 Net Income More Than Doubles to $47.35 Million
EARNINGS | Oct 27, 2026, 11:37 AM UTC
M
Kiniksa Reports Q3 2026 Financial Results
Kiniksa reported ARCALYST Q3 2026 net product revenue of $286.0 million, representing approximately 58% year over
EQUITY | Oct 27, 2026, 11:34 AM UTC
M
Kiniksa Expects 2026 Arcalyst Net Sales of $1.045-$1.050 Billion
EARNINGS | Oct 27, 2026, 11:33 AM UTC
M
Kiniksa Sees 2026 ARCALYST Net Product Revenue of $1.045B-$1.05B
EARNINGS | Oct 27, 2026, 11:32 AM UTC
M
Kiniksa Q3 Pretax Profit Reaches $59.057 Million
Kiniksa Pharmaceuticals reported Q3 pretax profit of USD 59.057 million. The headline also reports operating expenses of USD 231.734 million.
EQUITY | Oct 27, 2026, 11:31 AM UTC
M
Kiniksa Pharmaceuticals Reports 3Q Net of $47.3M
EARNINGS | Oct 27, 2026, 11:30 AM UTC
L
KNSA Q2 record revenue growth; 2026 guidance increased
Q2 delivered record revenue growth and the company increased 2026 guidance. ARCALYST reached 21% penetration in its core patient group, while pipeline assets including KPL-387 advanced.
EARNINGS | Sep 09, 2026, 01:53 PM UTC
L
Kiniksa management to join Wells Fargo healthcare conference fireside chat
Kiniksa Pharmaceuticals International said management will participate in a fireside chat at the Wells Fargo 21st Annual Healthcare Conference on Wednesday, September 9, 2026 at 8:45 a.m. Eastern Time.
EQUITY | Sep 04, 2026, 08:07 PM UTC
L
KNSA - Kiniksa Pharmaceuticals to Present at Wells Fargo 21st Annual Healthcare Conference
KNSA - Kiniksa Pharmaceuticals to Present at Wells Fargo 21st Annual Healthcare Conference
EQUITY | Sep 04, 2026, 08:01 PM UTC
L
KNSA Reiterate Buy, raise PT to $98 (from $64) after results @ Canaccord
KNSA Reiterate Buy, raise PT to $98 (from $64) after results @ Canaccord
EARNINGS | Jul 29, 2026, 12:46 PM UTC
H
KNSA Raised to $100 PT at Citi
Citi raises KNSA price target
EQUITY | Jul 29, 2026, 10:45 AM UTC
H
Crude Oil Down Over 5%; Boeing Shares Rise After Q2 Results
U.S. stocks traded mostly higher midway through trading, with the Dow Jones index gaining more than 1% on Tuesday. The Dow traded up 1.25% to 52,860.91 while the NASDAQ slipped 0.01% to 24,928.70. The S&P 500 also rose,
MACRO | Jul 28, 2026, 04:28 PM UTC
H
Sherwin-Williams Posts Upbeat Q2 Earnings, Joins Itron, Armstrong World And Other Big Stocks Moving Higher On Tuesday
U.S. stocks were mixed, with the Dow Jones index gaining around 300 points on Tuesday. Shares of Sherwin-Williams Co (NYSE: SHW ) rose sharply after the company reported better-than-expected second-quarter financial resu
EARNINGS | Jul 28, 2026, 02:05 PM UTC
L
Kiniksa raises FY26 revenue view to $980M-$995M from $930M-$945M
Consensus $940.13M. The...
EARNINGS | Jul 28, 2026, 11:46 AM UTC
L
Kiniksa reports Q2 EPS 30c, consensus 28c
Reports Q2 revenue...
EARNINGS | Jul 28, 2026, 11:45 AM UTC
L
Kiniksa Pharmaceuticals Raises FY2026 Sales Guidance from $930.000M-$945.000M to $980.000M-$995.000M vs $940.106M Est
Kiniksa Pharmaceuticals (NASDAQ: KNSA ) raises FY2026 sales outlook from $930.000 million-$945.000 million to $980.000 million-$995.000 million vs $940.106 million estimate.
EARNINGS | Jul 28, 2026, 11:30 AM UTC
L
KNSA Kiniksa Pharmaceuticals RESULTS: Q2, Q2 operating expenses $216.406M, Q2 Net Income $25.432M, Q2 pretax profit $31.145M, Kiniksa Pharma
KNSA Kiniksa Pharmaceuticals RESULTS: Q2, Q2 operating expenses $216.406M, Q2 Net Income $25.432M, Q2 pretax profit $31.145M, Kiniksa Pharmaceuticals Earnings Notes:, - Kiniksa Pharmaceuticals Q2 product REV $243.6M
EARNINGS | Jul 28, 2026, 11:30 AM UTC
M
Wedbush Maintains Outperform on Kiniksa Pharmaceuticals, Raises Price Target to $72
Wedbush analyst David Nierengarten maintains Kiniksa Pharmaceuticals (NASDAQ: KNSA ) with a Outperform and raises the price target from $59 to $72.
EQUITY | Jun 29, 2026, 01:32 PM UTC